Bausch + Lomb Corporation (BLCO)
NYSE: BLCO · Real-Time Price · USD
17.21
+0.03 (0.17%)
Oct 22, 2026, 10:32 AM EDT - Market open
Bausch + Lomb Revenue
Bausch + Lomb had revenue of $1.39B in the quarter ending June 30, 2026, with 9.08% growth. This brings the company's total for the last twelve months to $6.00B, up 9.28% year-over-year. In the year 2025, Bausch + Lomb had annual revenue of $5.10B with 6.47% growth. That makes Bausch + Lomb the 2,479th largest company in the world by revenue and 712th in the United States.
Revenue (ttm)
$6.00B
Revenue Growth
+9.28%
P/S Ratio
1.15
Revenue / Employee
$409,538
Employees
13,000
Market Cap
6.15B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Bausch + Lomb breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.10B | 310.00M | 6.47% |
| Dec 31, 2024 | 4.79B | 645.00M | 15.56% |
| Dec 31, 2023 | 4.15B | 378.00M | 10.03% |
| Dec 31, 2022 | 3.77B | 3.00M | 0.08% |
| Dec 31, 2021 | 3.77B | 353.00M | 10.35% |
| Dec 31, 2020 | 3.41B | -366.00M | -9.69% |
| Dec 31, 2019 | 3.78B | 113.00M | 3.08% |
| Dec 31, 2018 | 3.67B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| The Cooper Companies | 4.24B |
| Align Technology | 4.14B |
| AptarGroup | 3.93B |
| MiniMed Group | 3.22B |
| Envista Holdings | 2.86B |
| Teleflex | 2.25B |
| ICU Medical | 2.16B |
| Merit Medical Systems | 1.58B |
BLCO News
- 10 days ago - Bausch + Lomb names Thomas Appio as interim CEO - TheFly
- 10 days ago - Bausch + Lomb, Bausch Health expect to raise FY26 adjusted EBITDA, ex IPR&D - TheFly
- 10 days ago - Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance - Business Wire
- 15 days ago - Bausch + Lomb advances oral treatment for dry AMD after FDA meeting - TheFly
- 15 days ago - Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting - Business Wire
- 15 days ago - Bausch + Lomb initiated with an Overweight at Barclays - TheFly
- 17 days ago - Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28 - Business Wire
- 5 weeks ago - Bausch + Lomb announces European CE Mark approval of SeeLyra - TheFly